ReviewMediastinum (Hong Kong, China)2025
When rarity meets thoracic cancers: a narrative review from ITMIG 2024.
Review in Mediastinum (Hong Kong, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving paradigms in thymoma surgery and multidisciplinary care: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Rare thoracic cancers (RTCs) comprise a heterogeneous group of malignancies characterized by low incidence, high histological diversity, and significant clinical challenges. Their rarity often results in delayed diagnoses, lack of standardized therapeutic approaches, and limited prospective clinical trials. The absence of robust data is compounded by the fragmentation of expertise across institutions, underscoring the need for centralized, multidisciplinary management and international collaboration. This article aims to provide an overview of three representative RTC models, highlighting their unique clinical, pathological, and therapeutic features, and to discuss strategies for optimizing clinical care. Methods: A narrative review was conducted based on a targeted search of PubMed, MEDLINE, and major conference proceedings up to January 2025. The search focused on selected RTCs highlighted during the 2024 ITMIG annual meeting, using terms such as "SMARCA4-deficient undifferentiated tumors", "thymic neuroendocrine neoplasms", and "mediastinal germ cell tumors". Eligible sources included case reports, retrospective series, and narrative reviews. Only English-language publications were considered. Key Content and Findings: We focus on SMARCA4-deficient undifferentiated tumors as examples of rare entities newly defined by molecular profiling; thymic neuroendocrine neoplasms as ultra-rare and biologically aggressive neoplasms; and mediastinal germ cell tumors, which share biological traits with their gonadal counterparts but exhibit unique clinical behaviors. Through these models, we highlight common themes in RTCs management, including diagnostic uncertainty, limited therapeutic options, and emerging directions. Conclusions: We discuss the strengths and limitations of current evidence and future perspectives aimed at enhancing outcomes through dedicated registries and tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.